Farfield Collaborations

Farfield offers LayerLab's advance protocols for characterization of peptide-membrane and membrane protein interactions.

Farfield is pleased to be able to offer Layerlab's patented DNA tethered liposome kits for characterising peptide-membrane and membrane protein interactions. The kits offer DPI users a convenient and robust assay protocol for membrane and membrane protein studies and can be used in multilayer proteoliposome constructs for enhanced sensitivity. Combined with Farfield's unique measurement of liposome size density and mass, a data rich characterisation of the kinetic, affinity and mechanistic properties of interaction can be revealed. Learn more about Layerlab's technology.

Farfield Collaborative with IntelliHep on Glycan based surfaces

IntelliHep has developed a proprietary platform technology for the production of heparin-based glycan libraries exhibiting targeted diversity. These libraries enable the discovery and optimisation of novel lead compounds against specific disease applications. These libraries can be screened for activity and active glycans identified This collaboration will provide Farfield customers and even wider range of surfaces and a tailored surfaces for their glycan based studies. For more information visit http://www.intellihep.com.

Consortiums and Special Projects

Farfield joins Intopsens consortium

Farfield is pleased to be part of the research consortium called "INTOPSENS" combining leading research centres with industry across Europe. Intopsens will develop a highly integrated optical sensor for point of care label free identification of sepsis bacteria strains and their antibiotic resistance.
The project website address is http://www.ee.kth.se/intopsens/

Farfield joins ASMENA consortium to develop membrane protein assays

Farfield is a proud partner in the European FP7 programme ASMENA. The project will run over three years, and aims to develop new platforms for drug screening and analytical profiling based on in-vitro measurements of functional and conformational change in membrane proteins. The consortium consists of 15 partners in 7 countries and are world leading experts on surface functionalization, membrane self-assembly, biosensing and membrane protein functional measurements. Under this project their complementary competences can be put together on the European level to create a timely breakthrough in the area. More information can be obtained from the ASMENA website.

Farfield secures research funding for drug discovery from METRC (Molecular Engineering Translational Research Centre)

METRC is a virtual lab, pooling expertise from leading research centres at universities from the North of England. They specialise in soft nanotechnology research and applying this to industry and their current market focus includes medicine and healthcare. They are funded by N8 Research Partnerships and The Northern Way and have used this funding to help fund collaborations between their academic members and industry. Further information can be found on the METRC website.

Farfield Joins the Neurasyn Network to help Develop an Invitro Assays for Parkinson's Disease

Farfield Group are the successful recipients of a pan European Marie Curie Academic Industrial Training Program to research the molecular basis for the progression, inhibition and detection of Parkinson's Disease. The project participants who include collaborators in Germany, Greece, Portugal, Denmark, Sweden as well as the UK include some of Europe's foremost research laboratories in this field. Farfield, who will be leading on the development of a 'biosensor toolbox' based on their dual polarisation interferometer instrumentation. All interested applicants may contact Marcus Swann, mswann@farfield-group.com

Farfield is part of a Joint Industry Project supported by the Department of Business Innovation and Skills (DIUS) through the National Measurement Office's Measurement for Innovators Programme. Farfield are collaborating with the UK's National Physical Laboratory (NPL) and with University College London (UCL). The Project objectives are to define and characterise Farfield's sensor surfaces with the aim of developing validated protocols for near and in line biopharmaceutical manufacture quality control applications. The Project gives Farfield access to some of the world's best surface characterisation tools and biopharmaceutical manufacturing expertise. Already the project has identified enhanced cleaning and packaging protocols for sensors and quantified antibody capture surfaces for direct analysis of proteins in reactor broth. This brings Farfield's vision of introducing direct conformational analysis of proteins as they are manufactured one step closer to reality.

Further details can be found at the National Physics Laboratory and the Department of Biochemical Engineering at UCL.

Farfield Pan-European Collaboration with Sabio

Farfield Scientific has been awarded a prestigious contract as part of a pan-European research initiative to develop a diagnostic test for Hepatitis A, B and C. The project, code named SABIO, deploys one of the latest and most sensitive optical sensor technologies based on hollow or ‘slot' waveguides to detect multiple analytes in sera making it possible to test for Hepatitis A, B and C in a single, label free point of care assay. The collaboration between partners in Sweden, Austria, Spain, France, Belgium, Switzerland and Great Britain brings together a talented multidisciplinary team to diagnose one of the most common infectious diseases worldwide, second only to tuberculosis.

Farfield Scientific Launches Protein Crystallisation Initiative

Farfield Scientific Limited was awarded a research and development grant from the BBSRC under the Small Business Research Initiative (SBRI). The grant will enable Farfield to conduct new research into protein crystallisation. The aim of the project is to investigate the use of Farfield's proprietary optical waveguide technology to provide measurement tools to optimise the conditions for the crystallisation of diffraction quality protein crystals. For more information about the BBSRC: http://www.bbsrc.ac.uk/.

Farfield Collaborates with SMEs and Academic Institutions to Address the Challenges of Protein Crystallisation

OptiCryst's research platform aims to develop, implement and exploit new technologies to overcome the bottleneck of protein crystal optimisation. The OptiCryst consortium will develop research outputsaimed at crystallising proteins of high therapeutic value. The ultimate goal is to use this information for novel drug development. Farfield will refine screening and optimisation processes for proteins identified and partially characterised by other research groups in the consortium. It will become possible to produce high quality crystals from proteins which have previously proved difficult to crystallise. The number of proteins with clearly elucidated structures will increase rapidly, leading to breakthroughs in structural genomics. For more information visit http://www.opticryst.org.